Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome
Authors:
- 25 October 2017
- journal article
- research article
- Published by BMJ in Journal of Medical Genetics
- Vol. 55 (3) , 173-180
Abstract
Background: Development of tumours such as adrenocortical carcinomas (ACC), choroid plexus tumours (CPT) or female breast cancers before age 31 or multiple primary cancers belonging to the Li-Fraumeni (LFS) spectrum is, independently of the familial history, highly suggestive of a germline TP53 mutation. The aim of this study was to determine the contribution of de novo and mosaic mutations to LFS. Methods and results: Among 328 unrelated patients harbouring a germline TP53 mutation identified by Sanger sequencing and/or QMPSF, we could show that the mutations had occurred de novo in 40 cases, without detectable parental age effect. Sanger sequencing revealed two mosaic mutations in a child with ACC and in an unaffected father of a child with medulloblastoma. Re-analysis of blood DNA by next-generation sequencing, performed at a depth above 500X, from 108 patients suggestive of LFS without detectable TP53 mutations, allowed us to identify 6 additional cases of mosaic TP53 mutations, in 2/49 children with ACC, 2/21 children with CPT, in 1/31 women with breast cancer before age 31 and in a patient who developed an osteosarcoma at age 12, a breast carcinoma and a breast sarcoma at age 35. Conclusions: This study performed on a large series of TP53 mutation carriers allows estimating the contribution to LFS of de novo mutations to at least 14% (48/336) and suggests that approximately one-fifth of these de novo mutations occur during embryonic development. Considering the medical impact of TP53 mutation identification, medical laboratories in charge of TP53 testing should ensure the detection of mosaic mutations.Keywords
Funding Information
- the ARC Foundation for Cancer Research
- the INCa, the French National Cancer Institute
This publication has 42 references indexed in Scilit:
- Next generation sequencing is informing phenotype: a TP53 exampleFamilial Cancer, 2017
- Synonymous mutation in TP53 results in a cryptic splice site affecting its DNA‐binding site in an adolescent with two primary sarcomasPediatric Blood & Cancer, 2017
- Somatic Mosaic Mutations inPPM1DandTP53in the Blood of Women With Ovarian CarcinomaJAMA Oncology, 2016
- Unrevealed mosaicism in the next-generation sequencing eraMolecular Genetics and Genomics, 2015
- A child with Li–Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignanciesPediatric Blood & Cancer, 2015
- Anaplastic rhabdomyosarcoma in TP53 germline mutation carriersCancer, 2013
- De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous systemPediatric Blood & Cancer, 2009
- TP53 germline mutations in Portugal and genetic modifiers of age at cancer onsetFamilial Cancer, 2009
- Somatic TP53 mutation mosaicism in a patient with Li–Fraumeni syndromeAmerican Journal of Medical Genetics Part A, 2008
- Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss originCancer Genetics and Cytogenetics, 2004